PL3456190T3 - Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy - Google Patents

Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy

Info

Publication number
PL3456190T3
PL3456190T3 PL18183980T PL18183980T PL3456190T3 PL 3456190 T3 PL3456190 T3 PL 3456190T3 PL 18183980 T PL18183980 T PL 18183980T PL 18183980 T PL18183980 T PL 18183980T PL 3456190 T3 PL3456190 T3 PL 3456190T3
Authority
PL
Poland
Prior art keywords
antibody producing
producing transgenic
murine animal
transgenic murine
animal
Prior art date
Application number
PL18183980T
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Original Assignee
Merus N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3456190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus N.V. filed Critical Merus N.V.
Publication of PL3456190T3 publication Critical patent/PL3456190T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18183980T 2008-06-27 2009-06-29 Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy PL3456190T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27
EP09075279.1A EP2147594B1 (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
EP12175544.1A EP2556747B1 (en) 2008-06-27 2009-06-29 Antibody producing transgenic mice
EP18183980.4A EP3456190B1 (en) 2008-06-27 2009-06-29 Antibody producing transgenic murine animal

Publications (1)

Publication Number Publication Date
PL3456190T3 true PL3456190T3 (pl) 2022-06-06

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18183980T PL3456190T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
PL09075279T PL2147594T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała ssaki inne niż człowiek
PL18183994.5T PL3456192T3 (pl) 2008-06-27 2009-06-29 Zastosowanie wytwarzających przeciwciała ssaków z gatunku myszy do wytwarzania przeciwciał o wysokim powinowactwie

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL09075279T PL2147594T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała ssaki inne niż człowiek
PL18183994.5T PL3456192T3 (pl) 2008-06-27 2009-06-29 Zastosowanie wytwarzających przeciwciała ssaków z gatunku myszy do wytwarzania przeciwciał o wysokim powinowactwie

Country Status (23)

Country Link
EP (7) EP2556747B1 (pl)
JP (6) JP5749161B2 (pl)
KR (5) KR102112655B1 (pl)
CN (3) CN102123582B (pl)
AU (1) AU2009263082C1 (pl)
CA (1) CA2729095C (pl)
CY (2) CY1114830T1 (pl)
DK (4) DK2147594T3 (pl)
ES (4) ES2445193T3 (pl)
FI (1) FI3456192T3 (pl)
HR (3) HRP20251477T1 (pl)
HU (1) HUE057994T2 (pl)
LT (2) LT3456192T (pl)
MX (1) MX2010014542A (pl)
NZ (1) NZ590118A (pl)
PL (3) PL3456190T3 (pl)
PT (4) PT3456190T (pl)
RS (3) RS53146B (pl)
RU (2) RU2731084C2 (pl)
SG (3) SG10201914027VA (pl)
SI (3) SI2147594T1 (pl)
WO (1) WO2009157771A2 (pl)
ZA (1) ZA201009312B (pl)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
RU2731084C2 (ru) * 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
HRP20151188T4 (hr) * 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
CN103228130B (zh) * 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
PT3865581T (pt) * 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HRP20200744T1 (hr) 2011-12-22 2020-07-24 F. Hoffmann - La Roche Ag Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
NZ810648A (en) * 2012-02-01 2025-11-28 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
MX353278B (es) * 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
KR20150023535A (ko) * 2012-06-05 2015-03-05 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
EP4218409B1 (en) * 2013-03-13 2025-02-12 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
AU2014337526B2 (en) * 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SMT202500020T1 (it) 2014-02-28 2025-03-12 Merus Nv Anticorpo che lega erbb-2 ed erbb-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
IL257411B2 (en) 2015-08-24 2024-05-01 Trianni Inc Enhanced production of immunoglobulins
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
US11827876B2 (en) 2016-08-12 2023-11-28 Oxitec Ltd. Self-limiting, sex-specific gene and methods of using
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
CA3058342A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
CA3068929A1 (en) 2017-07-06 2019-01-10 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
EA202090005A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
MX2020000055A (es) 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
TW202438676A (zh) * 2017-12-05 2024-10-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
WO2019236671A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain ii
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN114344461A (zh) 2018-12-20 2022-04-15 美勒斯公司 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN114249823A (zh) * 2018-12-31 2022-03-29 美勒斯公司 混合的结合域
WO2020141974A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
EP3914622A1 (en) 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
IL285490B2 (en) 2019-02-14 2026-03-01 Merus Nv Combinations of binding sites that bind EGFR, HER2, and HER3
JP7375027B2 (ja) 2019-02-14 2023-11-07 メルス ナムローゼ フェンノートシャップ ２つ以上の抗体を含む組成物の製造
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
WO2021003149A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use
KR20220030956A (ko) * 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
WO2021020416A1 (ja) 2019-07-30 2021-02-04 小野薬品工業株式会社 二重特異性抗体
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
US20230084382A1 (en) 2019-08-19 2023-03-16 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
JP7633259B2 (ja) 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質
EP4097131A1 (en) 2020-01-29 2022-12-07 Merus N.V. Means and method for modulating immune cell engaging effects
CN115698067A (zh) 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
MX2023006983A (es) 2020-12-15 2023-06-26 Merus Nv Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).
US20240052050A1 (en) 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN117582496A (zh) 2020-12-18 2024-02-23 美勒斯公司 抗体组合物
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CA3237654A1 (en) 2021-10-06 2023-04-13 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
EP4469476A1 (en) 2022-01-25 2024-12-04 Merus N.V. Combination therapy for the treatment of cancer
EP4490190A1 (en) 2022-03-07 2025-01-15 Merus N.V. Treatment with an antibody that binds egfr and cmet
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
CN122031678A (zh) 2022-12-23 2026-05-15 美勒斯公司 使用至少结合egfr的抗体及免疫检查点抑制剂组合治疗癌症
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) * 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU3328493A (en) * 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
DK0979281T3 (da) * 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
AU754699C (en) * 1998-03-30 2003-05-15 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1970448A1 (en) * 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
RU2731084C2 (ru) * 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
HRP20151188T4 (hr) * 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
IT202300006069A1 (it) 2023-03-29 2024-09-29 Comecer Spa Contenitore modulare per trasportare radiofarmaci o farmaci termolabili

Also Published As

Publication number Publication date
EP4650441A3 (en) 2026-02-18
ES2445193T3 (es) 2014-02-28
AU2009263082C1 (en) 2018-11-01
JP2015156871A (ja) 2015-09-03
JP2022188085A (ja) 2022-12-20
CN105191863A (zh) 2015-12-30
PL2147594T3 (pl) 2014-04-30
EP3456192A1 (en) 2019-03-20
JP7242611B2 (ja) 2023-03-20
ZA201009312B (en) 2011-08-31
RU2731084C2 (ru) 2020-08-28
RS62925B1 (sr) 2022-03-31
ES3053014T3 (en) 2026-01-16
HRP20140139T1 (hr) 2014-03-14
JP2017121256A (ja) 2017-07-13
KR20170066688A (ko) 2017-06-14
RU2020127564A (ru) 2022-02-21
SG10201914027VA (en) 2020-03-30
EP3456190B1 (en) 2021-11-24
HRP20220205T1 (hr) 2022-05-27
RS67450B1 (sr) 2025-12-31
EP2147594B1 (en) 2013-11-13
NZ590118A (en) 2012-10-26
EP3456192B1 (en) 2025-09-03
DK3456190T3 (da) 2022-02-14
PT3456190T (pt) 2022-02-15
ES2906344T3 (es) 2022-04-18
SG10201914019YA (en) 2020-03-30
SI3456192T1 (sl) 2026-01-30
WO2009157771A2 (en) 2009-12-30
KR102112655B1 (ko) 2020-05-19
PT2556747T (pt) 2021-02-15
PT2147594E (pt) 2014-02-17
EP3456190A1 (en) 2019-03-20
WO2009157771A3 (en) 2010-02-18
EP3456193A1 (en) 2019-03-20
LT3456190T (lt) 2022-03-10
ES2853226T3 (es) 2021-09-15
DK2147594T3 (da) 2014-02-10
JP2020191882A (ja) 2020-12-03
HK1154463A1 (zh) 2012-04-27
RU2020127564A3 (pl) 2022-02-21
AU2009263082B2 (en) 2014-03-20
RU2015119670A3 (pl) 2019-01-22
KR20140127914A (ko) 2014-11-04
RU2011102962A (ru) 2012-08-10
FI3456192T3 (fi) 2025-12-03
EP2556747A3 (en) 2016-08-03
RU2559524C2 (ru) 2015-08-10
KR20190025068A (ko) 2019-03-08
PT3456192T (pt) 2025-11-19
RU2015119670A (ru) 2015-12-10
SG10201408500RA (en) 2015-01-29
AU2009263082B9 (en) 2014-07-17
EP2147594A1 (en) 2010-01-27
KR20200057093A (ko) 2020-05-25
MX2010014542A (es) 2011-04-05
SI2147594T1 (sl) 2014-02-28
DK2556747T3 (da) 2021-02-15
DK3456192T3 (da) 2025-11-24
RS53146B (sr) 2014-06-30
HRP20251477T1 (hr) 2026-01-16
CN112481300A (zh) 2021-03-12
EP3456191A1 (en) 2019-03-20
LT3456192T (lt) 2025-12-10
CY1114830T1 (el) 2016-12-14
JP5749161B2 (ja) 2015-07-15
HUE057994T2 (hu) 2022-06-28
EP2556747A2 (en) 2013-02-13
CN102123582B (zh) 2015-09-30
CY1125119T1 (el) 2023-06-09
JP6824807B2 (ja) 2021-02-03
JP7439201B2 (ja) 2024-02-27
KR102306491B1 (ko) 2021-09-29
CA2729095C (en) 2018-12-04
KR102261586B1 (ko) 2021-06-08
JP2011525808A (ja) 2011-09-29
CN102123582A (zh) 2011-07-13
PL3456192T3 (pl) 2026-02-23
EP2556747B1 (en) 2020-12-02
KR101990228B1 (ko) 2019-06-17
EP4650441A2 (en) 2025-11-19
CN105191863B (zh) 2020-12-22
JP2024063038A (ja) 2024-05-10
AU2009263082A1 (en) 2009-12-30
KR20110029156A (ko) 2011-03-22
SI3456190T1 (sl) 2022-06-30
CA2729095A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
SI3456190T1 (sl) Transgena mišja živali, ki proizvaja protitelesa
IL207217A0 (en) Humanized anti-c5ar antibodies
IL205906A0 (en) Antigen-binding constructs
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
ZA201102119B (en) Improved antibody libraies
ZA201104468B (en) Animal litters
ZA201008024B (en) Anti-flt3 antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
PL2262831T3 (pl) Przeciwciała przeciwko properdynie
GB2460160B (en) Fishing line guide
GB0821100D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
ZA201100905B (en) Transgenic plants
GB0805513D0 (en) Animal leash
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0816323D0 (en) Animal bedding
HU0800132D0 (en) Aquarium with brooder
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
AU2009905629A0 (en) Transgenic non-human animals
GB0813787D0 (en) Cat bell muffler